Blockade of Intranigral and Systemic D3 Receptors Stimulates Motor Activity in the Rat Promoting a Reciprocal Interaction among Glutamate, Dopamine, and GABA

Biomolecules. 2019 Sep 20;9(10):511. doi: 10.3390/biom9100511.

Abstract

In vivo activation of dopamine D3 receptors (D3Rs) depresses motor activity. D3Rs are widely expressed in subthalamic, striatal, and dendritic dopaminergic inputs into the substantia nigra pars reticulata (SNr). In vitro studies showed that nigral D3Rs modulate their neurotransmitter release; thus, it could be that these changes in neurotransmitter levels modify the discharge of nigro-thalamic neurons and, therefore, motor behavior. To determine how the in vitro responses correspond to the in vivo responses, we examined the effect of intra-nigral and systemic blockade of D3Rs in the interstitial content of glutamate, dopamine, and GABA within the SNr using microdialysis coupled to motor activity determinations in freely moving rats. Intranigral unilateral blockade of D3R with GR 103,691 increased glutamate, dopamine, and GABA. Increments correlated with increased ambulatory distance, non-ambulatory activity, and induced contralateral turning. Concomitant blockade of D3R with D1R by perfusion of SCH 23390 reduced the increase of glutamate; prevented the increment of GABA, but not of dopamine; and abolished behavioral effects. Glutamate stimulates dopamine release by NMDA receptors, while blockade with kynurenic acid prevented the increase in dopamine and, in turn, of GABA and glutamate. Finally, systemic administration of D3R selective antagonist U 99194A increased glutamate, dopamine, and GABA in SNr and stimulated motor activity. Blockade of intra-nigral D1R with SCH 23390 prior to systemic U 99194A diminished increases in neurotransmitter levels and locomotor activity. These data highlight the pivotal role of presynaptic nigral D3 and D1R in the control of motor activity and help to explain part of the effects of the in vivo administration of D3R agents.

Keywords: D1-like receptors; D3 receptors; substantia nigra reticulata; subthalamo–nigral pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzazepines / administration & dosage
  • Benzazepines / pharmacology
  • Biphenyl Compounds / administration & dosage*
  • Biphenyl Compounds / pharmacology
  • Dopamine / metabolism*
  • Glutamic Acid / metabolism*
  • Locomotion / drug effects
  • Male
  • Microdialysis
  • Piperazines / administration & dosage*
  • Piperazines / pharmacology
  • Rats
  • Receptors, Dopamine D3 / antagonists & inhibitors
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Substantia Nigra / metabolism*
  • Synaptic Transmission / drug effects
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • Benzazepines
  • Biphenyl Compounds
  • Piperazines
  • Receptors, Dopamine D3
  • Receptors, N-Methyl-D-Aspartate
  • SCH 23390
  • GR 103691
  • Glutamic Acid
  • gamma-Aminobutyric Acid
  • Dopamine